Here are the S-3 shelf registrations from Lifeward Ltd. (LFWD) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow LFWD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LFWD filings page.
Lifeward Ltd., an Israeli medical device company focused on exoskeletons and rehabilitation technologies, is registering for resale up to 2,066,662 ordinary shares. These consist of 1,033,331 shares issuable upon conversion of senior secured convertible notes and 1,033,331 shares issuable upon exercise of accompanying warrants from a June 30, 2026 Note and Warrant Financing.
The Initial Notes total $5,580,000 in principal, bear 8% annual interest, mature three years from their original issue date and are convertible at $5.40 per share. The Initial Warrants are immediately exercisable at $5.40 per share for five years. Lifeward is not selling shares in this offering and will receive no proceeds from Selling Shareholder resales, though it may receive cash from any warrant exercises for general corporate purposes. As of July 31, 2026, 2,828,362 ordinary shares were outstanding, and the Nasdaq Capital Market closing price was $7.22 under the symbol “LFWD.” The filing notes a 4.99% Beneficial Ownership Limitation for conversions and exercises and references an audit opinion containing a going concern explanatory paragraph.
Lifeward Ltd. has filed a prospectus for the resale by selling shareholders of up to 7,256,474 ordinary shares. The shares consist of issued shares and shares issuable upon exercise or conversion of a pre-funded warrant, transaction warrant, initial warrants and convertible notes issued in connection with the Strategic Acquisition.
The company is not selling shares here and will receive no proceeds from resales; selling shareholders will pay resale commissions. The prospectus cites a last reported sale price of $7.38 per share on April 24, 2026 and discloses certain shareholder ownership limits and plan‑of‑distribution methods.